Thomas Gad - 30 Sep 2021 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
Chairman, President and Head of Business Development & Strategy, Director
Signature
/s/ THOMAS GAD
Issuer symbol
YMAB
Transactions as of
30 Sep 2021
Transactions value $
-$113,054
Form type
4
Filing time
04 Oct 2021, 17:17:47 UTC
Previous filing
17 Sep 2021
Next filing
19 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Sale -$113K -4K -0.27% $28.26* 1.5M 30 Sep 2021 By GAD Enterprises LLC F1, F2, F3
holding YMAB Common Stock 50K 30 Sep 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2021
F2 This transaction was executed in multiple trades at prices ranging from $27.915 to $28.57. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.

Remarks:

Chairman, President and Head of Business Development & Strategy